What is actually coming
The most-asked question about hair loss is “when”. This is the only honest answer to it: the dates the running trials are due to report, exactly as their sponsors registered them.
These are not predictions, and they are not launch dates. A readout is the moment there will be news, and the news may be bad. Most of these programmes will fail.
Due to read out
- October 2026NXC736Phase 2NEXTGEN Bioscience· 73 participants
- December 2026VDPHL-01 (oral minoxidil)Phase 3Veradermics· 480 participants
- December 2026Ritlecitinib (Litfulo)Phase 3Pfizer· 208 participants
- January 2027OMA102Phase 3EMS· 504 participants
- March 2027Minoxidil (low-dose oral)Phase 2· 10 participants
- March 2027DA-001 / DA-002 / DA-005Phase 2/3Applied Biology· 1120 participants
- April 2027Delgocitinib (LEO 124249)Phase 2LEO Pharma· 30 participants
- May 2027Deuruxolitinib (Leqselvi)Phase 2/3Sun Pharmaceutical· 1000 participants
- May 2027SYHX1901Phase 2CSPC Pharmaceutical Group· 156 participants
- June 2027LY4005130Phase 2Eli Lilly· 60 participants
- June 2027VDPHL-01 (oral minoxidil)Phase 3Veradermics· 552 participants
- June 2027LAD603Phase 2Almirall· 136 participants
- July 2027Stem Cell Educator therapyPhase 2Throne Biotechnologies· 20 participants
- September 2027CKD-843Phase 3Chong Kun Dang Pharmaceutical· 288 participants
- October 2027Delgocitinib (LEO 124249)Phase 2LEO Pharma· 30 participants
- October 2027PyrilutamidePhase 2/3Kintor Pharmaceutical· 756 participants
Furthest along
Being in Phase 3 does not mean it works. It means a sponsor judged the question worth asking at scale.
- JaktinibApprovedSuzhou Zelgen Biopharmaceuticals
- Minoxidil (topical)Approved
- Ritlecitinib (Litfulo)ApprovedPfizer
- Baricitinib (Olumiant)ApprovedEli Lilly
- Upadacitinib (Rinvoq)ApprovedAbbVie
- Finasteride (Propecia)ApprovedOrganon
- Dutasteride (Avodart / Zagallo)ApprovedGSK
- Topical finasterideApprovedAlmirall
What moved recently
- August 2026VC005Phase 2
- July 2026Upadacitinib (Rinvoq)Approved
- July 2026APSMNFPhase 3
- April 2026LY4005130Phase 2
- April 2026TH07Phase 3
- January 2026Epibiotech dermal papilla cell therapyPhase 1/2
What this page will never do: announce a cure, rank treatments by expected efficacy, or give you a launch date. It is regenerated automatically from the trial registries — see how we track and the sources.